James B. Bingham
President chez Mmg Biopharmaceuticals Consulting LLC
Provenance du réseau au premier degré de James B. Bingham
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 18 | |
Amplimmune, Inc.
 Amplimmune, Inc. BiotechnologyHealth Technology Amplimmune, Inc. develops immune-based biological treatment for cancer and autoimmune diseases. The company was founded by Michael Richman, Charles G. Drake, Andrea Cox, Drew M. Pardoll, Jonathan D. Powell, Lieping Chen, David S. Kabakoff, and Elizabeth Jaffee in 2007 and is headquartered in Gaithersburg, MD.
10
| Extinct | Biotechnology | 10 |
| Holding Company | Pharmaceuticals: Generic | 6 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à James B. Bingham via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
MedImmune LLC
 MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Biotechnology | Chief Administrative Officer Corporate Officer/Principal | |
| PFIZER, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
| OSIRIS THERAPEUTICS, INC. | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| INTERMUNE INC | Biotechnology | Director/Board Member | |
| FIVE PRIME THERAPEUTICS, INC. | Biotechnology | Consultant / Advisor Director/Board Member | |
| SYNDAX PHARMACEUTICALS, INC. | Biotechnology | Chief Executive Officer | |
DNAtrix, Inc.
 DNAtrix, Inc. Electronic Equipment/InstrumentsElectronic Technology DNAtrix, Inc. operates as a biotech company which focuses on the development of oncolytic viruses for cancer. The firm’s offers DNX-2401 product which is an oncolytic virus designed specifically for treating Glioblastoma. It also works to expand its platform technology for treating other cancers, including ovarian, prostate and pancreatic cancer indications. The company was founded in 2005 by Francis Patrick McCormick, Alfred Yung, Charles Conrad, Cande Gomez-Manzano and Juan Fueyo and is headquartered in Houston, TX. | Electronic Equipment/Instruments | Director/Board Member | |
Arvinas Operations, Inc.
 Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Biotechnology | Chairman Director/Board Member Chief Executive Officer | |
Potenza Therapeutics, Inc.
 Potenza Therapeutics, Inc. BiotechnologyHealth Technology Potenza Therapeutics, Inc. develops oncology programs and mechanisms for tumors detection. It is focusing on the discovery and development of novel immune-oncology therapeutics: molecules that stimulate the power of the immune system to fight cancer. The company was founded by Drew M. Pardoll and Daniel J. Hicklin in 2014 and is headquartered in Cambridge, MA. | Biotechnology | Founder Corporate Officer/Principal | |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Undergraduate Degree Graduate Degree Undergraduate Degree | |
| MACROGENICS, INC. | Pharmaceuticals: Major | Chief Operating Officer Corporate Officer/Principal | |
| HBM HEALTHCARE INVESTMENTS AG | Investment Managers | Director/Board Member Director/Board Member | |
Broadpoint Securities, Inc.
 Broadpoint Securities, Inc. Investment Banks/BrokersFinance Part of Gleacher & Co., Inc., Broadpoint Securities, Inc. is a company that provides broker-dealer and investment banking services. The company is based in New York, NY. Broadpoint Securities was acquired by BroadPoint Securities Group, Inc. on May 17, 2004 for $32 million. | Investment Banks/Brokers | Corporate Officer/Principal | |
| The Johns Hopkins University | College/University | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| Yale University | College/University | Doctorate Degree Graduate Degree Undergraduate Degree | |
| The University of Colorado | College/University | Masters Business Admin Doctorate Degree | |
| Georgetown University | College/University | Undergraduate Degree | |
Nabriva Therapeutics GmbH
 Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Life Sciences Pennsylvania
 Life Sciences Pennsylvania Miscellaneous Commercial ServicesCommercial Services Life Sciences Pennsylvania (LSPA) is a trade association that represents various entities in the life sciences industry, including biotechnology, medical device, diagnostic, pharmaceutical, research, and investment companies, as well as service providers. The non-profit company is based in Wayne, PA and has subsidiaries in the United States. The organization unifies innovators in the state to make Pennsylvania a leader in the life sciences industry. Founded in 1989, LSPA aims to create a business and public policy environment that encourages and incentivizes the diverse life sciences economy in Pennsylvania. Christopher P. Molineaux has been the CEO of the company since 2009. | Miscellaneous Commercial Services | Director/Board Member | |
The Sidney Kimmel Comprehensive Cancer Center
 The Sidney Kimmel Comprehensive Cancer Center Hospital/Nursing ManagementHealth Services The Sidney Kimmel Comprehensive Cancer Center offers immune-based treatments for cancer. The company was founded by Sidney Kimmel in 1973 and is headquartered in Baltimore, MD. | Hospital/Nursing Management | Director/Board Member | |
RareCyte, Inc.
 RareCyte, Inc. Medical SpecialtiesHealth Technology RareCyte Inc. develops life science research and diagnostic that focuses on characterizing and isolating rare cells in the blood. It engages in bringing its technology to the life sciences research, drug development and diagnostic markets providing new tools to answer difficult questions related to cancer and cardiovascular disease. It's ground-breaking sccuCyte system is an open platform for the unbiased discovery and isolation of circulating tumor cells and circulating endothelial cells from whole blood. The company was founded by Ronald Seubert in 2009 and is headquartered in Seattle, WA. | Medical Specialties | Director/Board Member Director/Board Member | |
Nuron Biotech, Inc.
 Nuron Biotech, Inc. BiotechnologyHealth Technology Nuron Biotech, Inc. markets and develops vaccines for the prevention and treatment of infectious diseases. It develops novel biologics and vaccines for the prevention and treatment of neurodegenerative and infectious diseases. The firm is advancing products to meet unmet medical needs in the areas of multiple sclerosis, alzheimer's, hepatitis b and hepatitis c for patients across the globe. The company was founded by Vithalbhai Dhaduk, Shankar Musunuri and David Zeng in 2009 and is headquartered in Exton, PA. | Biotechnology | Director/Board Member | |
| JOUNCE THERAPEUTICS, INC. | Miscellaneous Commercial Services | Founder | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin | |
| Yale School of Medicine | College/University | Corporate Officer/Principal Corporate Officer/Principal | |
| The University of Connecticut School of Medicine | College/University | Doctorate Degree Doctorate Degree | |
| SPARK THERAPEUTICS, INC. | Biotechnology | Director of Finance/CFO | |
Transcelerate Biopharma, Inc.
 Transcelerate Biopharma, Inc. BiotechnologyHealth Technology Transcelerate Biopharma, Inc. is a non-profit consortium that collaborates with pharmaceutical and biotechnology companies to improve the delivery of new medicines. The non-profit company is based in King of Prussia, PA. The organization's mission is to identify, prioritize, design, and facilitate implementation of solutions to drive the efficient, effective, and high-quality delivery of new medicines. Transcelerate has 20 member companies and 30+ initiatives focused on improving the patient and site experience, enhancing sponsor efficiencies and drug safety, and harmonizing processes and sharing information. The company was founded by Garry Arthur Neil, and Janice Chang has been the CEO of the company since 2014. | Biotechnology | Chairman | |
| VIKING THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| CYTOMX THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| PIERIS PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member Chairman | |
| GRITSTONE BIO, INC. | Biotechnology | Chairman Director/Board Member Director/Board Member | |
| ARVINAS, INC. | Biotechnology | Chief Executive Officer Director/Board Member Chief Executive Officer | |
Tmunity Therapeutics, Inc.
 Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Tizona Therapeutics, Inc.
 Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Biotechnology | Founder Founder | |
| TCR2 THERAPEUTICS INC. | Pharmaceuticals: Major | Chairman | |
Alliance for Clinical Research Excellence & Safety
 Alliance for Clinical Research Excellence & Safety Miscellaneous Commercial ServicesCommercial Services Alliance for Clinical Research Excellence & Safety is a non-governmental organization that builds, implements, and maintains comprehensive systems. The non-profit company is based in Cambridge, MA. The company was founded by Greg Koski. | Miscellaneous Commercial Services | Director/Board Member | |
| NABRIVA THERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
ImVax, Inc.
 ImVax, Inc. BiotechnologyHealth Technology ImVax, Inc. provides healthcare services. The company was founded in 2015 and is headquartered in Philadelphia, PA. | Biotechnology | Director/Board Member | |
Dracen Pharmaceuticals, Inc.
 Dracen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dracen Pharmaceuticals, Inc. develops immuno-metabolism drugs. The company was founded by Barbara Slusher, Jonathan D. Powell, Pavel Majer, and Rana Rais and is headquartered in New York, NY. | Pharmaceuticals: Major | Director/Board Member Founder | |
Spark Therapeutics UK Ltd.
 Spark Therapeutics UK Ltd. Medical/Nursing ServicesHealth Services Part of Roche Holding AG, Spark Therapeutics UK Ltd. is a healthcare services provider. The company is based in London, UK. Spark Therapeutics was founded in 2016. | Medical/Nursing Services | Director/Board Member | |
Ervaxx Ltd.
 Ervaxx Ltd. Pharmaceuticals: MajorHealth Technology Ervaxx Ltd. is a British company that pioneers the use of dark antigens to deliver targeted immunotherapies for treating and preventing cancer. The company was founded in 2016 by George Kassiotis, Drew M. Pardoll and is based in London, UK. The company's powerful, proprietary edapt platform has been developed to discover and validate dark antigens providing an in-depth assessment of candidate antigens on primary tumor cells along with their immunogenic potential. Ervaxx is advancing a pipeline of T cell receptor-based therapies, off-the-shelf cancer vaccines, and other immunotherapies leveraging these insights into the role of dark antigens in cancer. | Pharmaceuticals: Major | Founder | |
Catalio Capital Management LP
 Catalio Capital Management LP Investment ManagersFinance Catalio Capital Management LP (Catalio Capital) is a venture capital firm founded in 2020 by George Petrocheilos and Dr. Jacob Vogelstein. The firm is headquartered in New York. | Investment Managers | Consultant / Advisor Private Equity Investor | |
| CULLINAN THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member |
Statistiques
Internationale
| Etats-Unis | 44 |
| Royaume-Uni | 4 |
| Suisse | 2 |
| Allemagne | 2 |
| Autriche | 2 |
Sectorielle
| Health Technology | 30 |
| Consumer Services | 9 |
| Finance | 6 |
| Commercial Services | 5 |
| Health Services | 4 |
Opérationnelle
| Director/Board Member | 209 |
| Corporate Officer/Principal | 70 |
| Independent Dir/Board Member | 62 |
| Chairman | 29 |
| Chief Tech/Sci/R&D Officer | 21 |
Relations les plus connectées
| Insiders | |
|---|---|
| Chau Khuong | 38 |
| Elaine Jones | 37 |
| David Kabakoff | 30 |
| Timothy Shannon | 28 |
| Briggs Morrison | 26 |
| Stephen Webster | 23 |
| John Leone | 21 |
| Daniel Marshak | 21 |
| Michael Richman | 16 |
| Garry Nicholson | 16 |
| Judith Li | 15 |
| Stella Xu | 14 |
| John Houston | 11 |
| Drew Pardoll | 11 |
| Solomon Langermann | 10 |
- Bourse
- Insiders
- James B. Bingham
- Connexions Sociétés
